UnitedHealth Stock Falls Amid DOJ Fraud Probe

The U.S. Department of Justice has launched a civil fraud investigation into UnitedHealth Group over its Medicare Advantage billing practices, specifically whether the company has been inflating diagnoses to receive higher payments. This probe has led to a significant drop in UnitedHealth's stock, with shares falling nearly 20% and affecting the broader healthcare sector. UnitedHealth denies the allegations, calling them false and outrageous, and disputes the Wall Street Journal's reporting on the matter. Analysts remain divided, with some viewing the stock's decline as an overreaction, citing the company's strong fundamentals and potential for long-term growth. In addition to this investigation, UnitedHealth is also facing ongoing antitrust scrutiny related to its acquisition activities. The implications of the investigation are significant, as it could lead to financial penalties or operational changes for UnitedHealth if wrongdoing is found.